Trials / Completed
CompletedNCT01187303
Ofatumumab in Nodular Lymphocyte Predominant Hodgkin Lymphoma (NLPHL)
Ofatumumab in Relapsed Nodular Lymphocyte Predominant Hodgkin Lymphoma (NLPHL)
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 28 (actual)
- Sponsor
- University of Cologne · Academic / Other
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this trial is to determine the efficacy of ofatumumab in patients with relapsed nodular lymphocyte predominant Hodgkin lymphoma (NLPHL).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Ofatumumab | 300 mg/m2 d1 week 1 1000mg/m2 d1 week 2-8 |
Timeline
- Start date
- 2011-05-01
- Primary completion
- 2013-11-01
- Completion
- 2015-09-01
- First posted
- 2010-08-24
- Last updated
- 2015-11-02
Locations
1 site across 1 country: Germany
Source: ClinicalTrials.gov record NCT01187303. Inclusion in this directory is not an endorsement.